Development and validation of a nomogram for predicting stroke risk in rheumatoid arthritis patients

Development and validation of a risk prediction model for arthritis in community-dwelling middle-aged and older adults in China

Background

Considering its high prevalence, estimating the risk of arthritis in middle-aged and older Chinese adults is of particular interest. This study was conducted to develop a risk prediction model for arthritis in community-dwelling middle-aged and older adults in China.

Methods

Our study included a total of 9599 participants utilising data from the China Health and Retirement Longitudinal Study (CHARLS). Participants were randomly assigned to training and validation groups at a 7:3 ratio. Univariate and multivariate binary logistic regression analyses were used to identify the potential predictors of arthritis. Based on the results of the multivariate binary logistic regression, a nomogram was constructed, and its predictive performance was evaluated using the receiver operating characteristic (ROC) curve. The accuracy and discrimination ability were assessed using calibration curve analysis, while decision curve analysis (DCA) was performed to evaluate the net clinical benefit rate.

Results

A total of 9599 participants were included in the study, of which 6716 and 2883 were assigned to the training and validation groups, respectively. A nomogram was constructed to include age, hypertension, heart diseases, gender, sleep time, body mass index (BMI), residence address, the parts of joint pain, and trouble with body pains. The results of the ROC curve suggested that the prediction model had a moderate discrimination ability (AUC >0.7). The calibration curve of the prediction model demonstrated a good predictive accuracy. The DCA curves revealed a favourable net benefit for the prediction model.

Conclusions

The predictive model demonstrated good discrimination, calibration, and clinical validity, and can help community physicians and clinicians to preliminarily assess the risk of arthritis in middle-aged and older community-dwelling adults.

Development and internal validation of a risk model for hyperuricemia in diabetic kidney disease patients

Purpose

This research aimed to identify independent risk factors for hyperuricemia (HUA) in diabetic kidney disease (DKD) patients and develop an HUA risk model based on a retrospective study in Ningbo, China.

Patients and methods

Six hundred and ten DKD patients attending the two hospitals between January 2019 and December 2020 were enrolled in this research and randomized to the training and validation cohorts based on the corresponding ratio (7:3). Independent risk factors associated with HUA were identified by multivariable logistic regression analysis. The characteristic variables of the HUA risk prediction model were screened out by the least absolute shrinkage and selection operator (LASSO) combined with 10-fold cross-validation, and the model was presented by nomogram. The C-index and receiver operating characteristic (ROC) curve, calibration curve and Hosmer-Lemeshow test, and decision curve analysis (DCA) were performed to evaluate the discriminatory power, degree of fitting, and clinical applicability of the risk model.

Results

Body mass index (BMI), HbA1c, estimated glomerular filtration rate (eGFR), and hyperlipidemia were identified as independent risk factors for HUA in the DKD population. The characteristic variables (gender, family history of T2DM, drinking history, BMI, and hyperlipidemia) were screened out by LASSO combined with 10-fold cross-validation and included as predictors in the HUA risk prediction model. In the training cohort, the HUA risk model showed good discriminatory power with a C-index of 0.761 (95% CI: 0.712-0.810) and excellent degree of fit (Hosmer-Lemeshow test, P > 0.05), and the results of the DCA showed that the prediction model could be beneficial for patients when the threshold probability was 9-79%. Meanwhile, the risk model was also well validated in the validation cohort, where the C-index was 0.843 (95% CI: 0.780-0.906), the degree of fit was good, and the DCA risk threshold probability was 7-100%.

Conclusion

The development of risk models contributes to the early identification and prevention of HUA in the DKD population, which is vital for preventing and reducing adverse prognostic events in DKD.

Artificial Intelligence in Rheumatoid Arthritis: Current Status and Future Perspectives: A State-of-the-Art Review

Investigation of the potential applications of artificial intelligence (AI), including machine learning (ML) and deep learning (DL) techniques, is an exponentially growing field in medicine and healthcare. These methods can be critical in providing high-quality care to patients with chronic rheumatological diseases lacking an optimal treatment, like rheumatoid arthritis (RA), which is the second most prevalent autoimmune disease. Herein, following reviewing the basic concepts of AI, we summarize the advances in its applications in RA clinical practice and research. We provide directions for future investigations in this field after reviewing the current knowledge gaps and technical and ethical challenges in applying AI. Automated models have been largely used to improve RA diagnosis since the early 2000s, and they have used a wide variety of techniques, e.g., support vector machine, random forest, and artificial neural networks. AI algorithms can facilitate screening and identification of susceptible groups, diagnosis using omics, imaging, clinical, and sensor data, patient detection within electronic health record (EHR), i.e., phenotyping, treatment response assessment, monitoring disease course, determining prognosis, novel drug discovery, and enhancing basic science research. They can also aid in risk assessment for incidence of comorbidities, e.g., cardiovascular diseases, in patients with RA. However, the proposed models may vary significantly in their performance and reliability. Despite the promising results achieved by AI models in enhancing early diagnosis and management of patients with RA, they are not fully ready to be incorporated into clinical practice. Future investigations are required to ensure development of reliable and generalizable algorithms while they carefully look for any potential source of bias or misconduct. We showed that a growing body of evidence supports the potential role of AI in revolutionizing screening, diagnosis, and management of patients with RA. However, multiple obstacles hinder clinical applications of AI models. Incorporating the machine and/or deep learning algorithms into real-world settings would be a key step in the progress of AI in medicine.